GSK plc (LON:GSK) Receives GBX 1,829.17 Average Price Target from Brokerages

Shares of GSK plc (LON:GSK) have been given an average recommendation of “Hold” by the seven analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is GBX 1,839.29.

A number of equities analysts recently weighed in on GSK shares. Deutsche Bank Aktiengesellschaft upped their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research report on Thursday, January 15th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Citigroup reaffirmed a “buy” rating and issued a GBX 1,900 target price on shares of GSK in a report on Tuesday. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a research report on Wednesday, January 7th. Finally, Shore Capital reissued a “buy” rating on shares of GSK in a research note on Thursday, January 8th.

Insider Buying and Selling

In other GSK news, insider Jonathan Symonds purchased 1,650 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average price of GBX 1,810 per share, with a total value of £29,865. Also, insider Wendy Becker acquired 441 shares of the stock in a transaction on Friday, December 19th. The shares were acquired at an average price of GBX 1,809 per share, with a total value of £7,977.69. 0.20% of the stock is currently owned by corporate insiders.

GSK Stock Down 0.4%

LON GSK opened at GBX 1,844 on Friday. GSK has a 12 month low of GBX 1,242.50 and a 12 month high of GBX 1,909.73. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The stock has a market cap of £74.39 billion, a PE ratio of 13.86, a P/E/G ratio of 1.24 and a beta of 0.31. The stock’s 50 day moving average is GBX 1,821.44 and its 200 day moving average is GBX 1,641.33.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Research analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.